These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 36921693)
1. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693 [TBL] [Abstract][Full Text] [Related]
2. Real-world first-line treatment of patients with BRAF Martinelli E; Cremolini C; Mazard T; Vidal J; Virchow I; Tougeron D; Cuyle PJ; Chibaudel B; Kim S; Ghanem I; Asselain B; Castagné C; Zkik A; Khan S; Arnold D ESMO Open; 2022 Dec; 7(6):100603. PubMed ID: 36368253 [TBL] [Abstract][Full Text] [Related]
3. WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF Shimozaki K; Hirata K; Sato T; Nakamura M; Kato K; Hirano H; Kumekawa Y; Hino K; Kawakami K; Kito Y; Matsumoto T; Kawakami T; Komoda M; Nagashima K; Sato Y; Yamazaki K; Hironaka S; Takaishi H; Hamamoto Y; Muro K Clin Colorectal Cancer; 2022 Dec; 21(4):339-346. PubMed ID: 36117091 [TBL] [Abstract][Full Text] [Related]
4. Impact of Metastasectomy in the Multimodality Approach for Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173 [TBL] [Abstract][Full Text] [Related]
5. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of Lynch syndrome, BRAF Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121 [TBL] [Abstract][Full Text] [Related]
8. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476 [TBL] [Abstract][Full Text] [Related]
9. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M; BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148 [TBL] [Abstract][Full Text] [Related]
10. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913 [TBL] [Abstract][Full Text] [Related]
11. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393 [TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China. Xu Y; Wang G; Zheng X; Chang W; Fu J; Zhang T; Lin Q; Lv Y; Zhu Z; Tang W; Xu J Eur J Surg Oncol; 2023 Nov; 49(11):106981. PubMed ID: 37455182 [TBL] [Abstract][Full Text] [Related]
13. A validated prognostic classifier for Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218 [TBL] [Abstract][Full Text] [Related]
15. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer. Xu T; Li J; Wang Z; Zhang X; Zhou J; Lu Z; Shen L; Wang X Cancer Med; 2023 May; 12(9):10473-10484. PubMed ID: 36912150 [TBL] [Abstract][Full Text] [Related]
16. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795 [TBL] [Abstract][Full Text] [Related]
18. Metastatic pattern is a prognostic factor in BRAF Ji J; Sandhu J; Wang C; Fakih M Cancer Treat Res Commun; 2023; 35():100714. PubMed ID: 37126990 [TBL] [Abstract][Full Text] [Related]
19. Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF García-Alfonso P; Lièvre A; Loupakis F; Tadmouri A; Khan S; Barcena L; Stintzing S Crit Rev Oncol Hematol; 2022 May; 173():103646. PubMed ID: 35344913 [TBL] [Abstract][Full Text] [Related]
20. Clinical Validation of Plasma-Based Genotyping for Aoki Y; Nakamura Y; Denda T; Ohta T; Esaki T; Shiozawa M; Yamaguchi K; Yamazaki K; Sunakawa Y; Kato T; Okano N; Taniguchi H; Sato T; Oki E; Nishina T; Komatsu Y; Matsuhashi N; Goto M; Yasui H; Ohtsubo K; Moriwaki T; Takahashi N; Horita Y; Boku S; Wakabayashi M; Ikeno T; Mitani R; Yuasa M; Yoshino T JCO Precis Oncol; 2023 Jun; 7():e2200688. PubMed ID: 37343204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]